Core Insights - PTC has launched Creo 12, a new version of its CAD solution aimed at enhancing design efficiency and collaboration for manufacturers [1][2] - The update includes hundreds of enhancements across design, simulation, and manufacturing capabilities, promoting smarter workflows and increased productivity [1][7] Product Features - Creo 12 introduces new links to engineering material data in PTC's Windchill PLM solution, supporting sustainability by improving visibility into material choices and their environmental impacts [2] - The latest version of Creo+ is now available, offering cloud-enabled collaboration and entitlement tools [2] Demonstration and Market Engagement - PTC will showcase Creo 12 at the International Paris Air Show from June 16 to 22, 2025, highlighting its application in the aerospace sector through partnerships with companies like Hill Helicopters [3] Company Overview - PTC is a global software company based in Boston, employing over 7,000 people and serving more than 30,000 customers worldwide [4]

Core Insights - Absci Corporation has initiated dosing of participants in the first-in-human study of ABS-101, an anti-TL1A antibody, with interim data expected in the second half of 2025 [1][5] - The company has released non-human primate data for ABS-201, an anti-PRLR antibody, showing extended half-life and high subcutaneous bioavailability, with Phase 1 initiation anticipated in early 2026 [1][5] - Absci's cash, cash equivalents, and short-term investments are sufficient to fund operations into the first half of 2027 [1][6] Internal Pipeline Updates - The first-in-human study of ABS-101 is a randomized, double-blind, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in approximately 40 healthy adult participants [5] - ABS-201 is being developed for androgenetic alopecia, targeting a significant unmet clinical need with a potential patient population of around 80 million in the U.S. [5] - The NHP study for ABS-201 demonstrated a high subcutaneous bioavailability of over 90% and the potential for Q8W-Q12W dosing intervals in humans [5] Financial Results - For Q1 2025, Absci reported revenue of $1.2 million, an increase from $0.9 million in Q1 2024 [7] - Research and development expenses rose to $16.4 million in Q1 2025 from $12.2 million in Q1 2024, driven by advancements in internal programs [8] - The net loss for Q1 2025 was $26.3 million, compared to $22.0 million in Q1 2024 [9] Cash Position - As of March 31, 2025, Absci had cash, cash equivalents, and short-term investments totaling $134.0 million, up from $112.4 million at the end of 2024 [10]